HutchMED (China) LIMITED HMDCF
Annual
Quarterly
FY2025 · ended Dec 31, 2025 · Revenue $548.51M, -13.0% YoY · Filed Mar 5, 2026
HutchMED (China) LIMITED (HCM) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $548.5 million and net income of $456.9 million. Free cash flow was -$78.8 million. As of Dec 31, 2025 it held $1.4 billion in cash and investments and $122.9 million in total debt.
Revenue
$548.51M
-13.0% vs prior year
Net income
$456.91M
+1111.0% vs prior year
Operating cash flow
$-64.66M
-13109.5% vs prior year
Free cash flow
$-78.81M
-352.0% vs prior year
EPS
$0.52
+1200.0% vs prior year
Dividend per share
None
Shares outstanding
872.33M
+0.1% vs prior year
Net cash
$1.24B
FY 2025
Operating margin
-7.1%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HCM (Nasdaq), HMDCF (OTC)
- Incorporated in
- Cayman Islands
- Headquarters
- Hong Kong
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1648257
- Former names
- Hutchison China MediTech Ltd (until Apr 29, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $548.5M | $630.2M | $838.0M | $426.4M | $356.1M |
| Operating income | -$39.2M | -$43.7M | $18.4M | -$407.7M | -$328.3M |
| Net income | $456.9M | $37.7M | $100.8M | -$360.8M | -$194.6M |
| Diluted EPS | $0.52 | $0.04 | $0.12 | -$0.43 | -$0.25 |
| Operating cash flow | -$64.7M | $497,000 | $219.3M | -$268.6M | -$204.2M |
| Free cash flow | -$78.8M | -$17.4M | $186.6M | -$305.3M | -$220.6M |
| Total assets | $1.8B | $1.3B | $1.3B | $1.0B | $1.4B |
| Total liabilities | $501.8M | $502.3M | $536.4M | $392.6M | $333.1M |
| Stockholders' equity | $1.2B | $759.9M | $730.5M | $610.4M | $986.9M |
| Cash and investments | $1.4B | $836.1M | $886.3M | $631.0M | $1.0B |
| Total debt | $122.9M | $113.2M | $117.3M | $27.0M | $39.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 5, 2026 | Nov 5, 2026 |
| 6-K | Current report (foreign issuer) | Nov 2, 2026 | Nov 2, 2026 |
| 6-K | Current report (foreign issuer) | Oct 29, 2026 | Oct 29, 2026 |
| 6-K | Current report (foreign issuer) | Oct 27, 2026 | Oct 27, 2026 |
| 6-K | Current report (foreign issuer) | Oct 26, 2026 | Oct 26, 2026 |
| 6-K | Current report (foreign issuer) | Oct 21, 2026 | Oct 21, 2026 |
All 611 HutchMED (China) LIMITED SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.